In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Good News for a Small-Cap Imaging Company

Executive Summary

Schering AG's purchase of Diatide Inc. appears to be an exception to the general rule that, while small-cap acquisitions are at an all-time high, the shareholders of acquired companies don't fare particularly well. Schering areed to pay a significant premium over the the Diatide stock price just prior to the deal, despite the fact that Nycomed Amersham PLC owns partial rights to Diatides two late-stage products. Schering was willing to pay the price because of its commitment to developing a franchise in nuclear imaging.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel